Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 12/20 | 0.51 |
| ▸ | AR | P10275 | 5/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.51 |
| ▸ | PGR | P06401 | 3/20 | 0.51 |
| ▸ | RAF1 | P04049 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4297408 | 0.91 | NR3C2 (0.52) | NR3C2ARNR3C1PGRRAF1 | |
| SCHEMBL4290825 | 0.90 | NR3C2 (0.56) | NR3C2ARNR3C1PGRPDE3B | |
| SCHEMBL4288373 | 0.87 | NR3C2 (0.54) | NR3C2ARNR3C1PGRMAPT | |
| SCHEMBL4291210 | 0.82 | NR3C2 (0.58) | NR3C2ARNR3C1PGR | |
| SCHEMBL4290948 | 0.81 | NR3C2 (0.54) | NR3C2ARNR3C1PGRPDE3B | |
| SCHEMBL4288429 | 0.81 | NR3C2 (0.57) | NR3C2ARNR3C1PGRPDE3B | |
| SCHEMBL4295836 | 0.77 | NR3C2 (0.54) | NR3C2ARNR3C1PGRPDE3B | |
| SCHEMBL4290883 | 0.77 | KDM4E (0.56) | NR3C2ARNR3C1PGRPDE3B | |
| SCHEMBL4295501 | 0.77 | NR3C2 (0.53) | NR3C2ARNR3C1PGRLMNA | |
| SCHEMBL4297385 | 0.77 | NR3C2 (0.55) | NR3C2ARNR3C1PGRPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | US | disclosed |
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | US | disclosed |
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | US | disclosed |
| WO-2007077961-A2 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS MINERALOCORTICOID RECEPTOR LIGANDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | NR3C2, NR3C1, MC2R | NR3C2 1/4885AR 60/4885NR3C1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.